Evidence map›Paper›PMID 41574313›Full record

ArticleBlood neoplasia2026

Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors.

Alex C H Liu, Severine Cathelin, Dhanoop Manikoth Ayyathan, Yitong Yang, Farzaneh Aboualizadeh, Amina Abow, Gurbaksh Basi, Lance Li, David L Dai, Abdula Maher and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Alex C H LiuPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Severine CathelinPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Dhanoop Manikoth AyyathanPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Yitong YangPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Farzaneh AboualizadehPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Amina AbowPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Gurbaksh BasiPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Lance LiPrincess Margaret Cancer Centre, Toronto, ON, Canada.
David L DaiPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Abdula MaherPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Eric GrignanoPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Mohsen HosseiniPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Vivian WangPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Troy KetelaPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Brandon NicolayAgios Pharmaceuticals, Inc, Cambridge, MA.
Dylan M MarchioneServier Pharmaceuticals, LLC, Boston, MA.
Adriana E TronServier Pharmaceuticals, LLC, Boston, MA.
Andrea ArrudaPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Mark D MindenPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Steven M ChanPrincess Margaret Cancer Centre, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clonal heterogeneity in acute myeloid leukemia (AML) can drive drug resistance because different clones may respond variably to treatments. Studying the evolution of these clones under the influence of therapeutic selective pressures is important for designing strategies to overcome drug resistance. Here, we used single-cell proteogenomic analysis to monitor the clonal evolution and differentiation of isocitrate dehydrogenase (

Identifiers

PMID41574313
PMCPMC12820584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.